This week's Fierce Biotech is brought to you by Sartorius Corporation. Trouble viewing? Click here.
Mesenchymal stem cells (MSCs) have been used extensively in cell therapy applications. In order to generate sufficient quantities of cells for clinical applications, MSCs must be transitioned from static 2D cultures to scalable suspension cultures grown in bioreactors. This transfer has traditionally represented a bottleneck. This App Note demonstrates establishment of process control early in process development to overcome this bottleneck to help decrease development times and reduce COGs. Combined with automation, this approach facilitates transfer and scale-up in later stages of development by enabling the development of process insight and rapid identification and optimization of critical process parameters (CPPs).
Published by Sartorius AG Otto-Brenner-Straße 20 37079 Goettingen, Germany Phone +49 551 308-0 Fax +49 551 308-3289 info@sartorius.com sartorius.com
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy.
Questex, LLC 685 3rd Avenue, 21st Floor New York, NY 10017
